Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy.
Total triterpenic fraction of Centella asiatica (TTFCA) is effective in improving venous wall alterations in chronic venous hypertension and in protecting the venous endothelium. TTFCA is active on connective tissue modulation, improves the synthesis of collagen and other tissue proteins by modulating the action of fibroblasts in the vein wall, and stimulates collagen remodeling in and around the venous wall. This is due to the modulating action of TTFCA on fibroblasts as shown by experiments on the growth of human embryonal fibroblasts. TTFCA has a moderate in-vitro and in-vivo stimulating effect on collagen synthesis and, at higher dosages, an inhibition on the synthesis of collagen and acid mucopolysaccharides. Studies have indicated the role of TTFCA on the synthesis of specific venous wall elements by cell cultures of human embryonal fibroblasts. The tissue-stimulating action is shown by the increased collagen production independent from the stimulation of cell proliferation (this differentiates the action of TTFCA from cell growth factors). TTFCA is active on the microcirculation in venous and diabetic microangiopathy. Signs and symptoms of venous hypertension and edema are improved by treatment. The remodeling on collagen synthesis could be one of the possible mechanisms of actions of TTFCA in the remodeling of echolucent (soft; therefore, with risk of thrombosis and embolization) plaques at the carotid and femoral bifurcation. This compound is safe and well tolerated. In conclusion, several actions of TTFCA in vascular diseases makes the use of this compound very interesting in venous and arterial problems.
Incandela
L
L
Vascular Unit, Ealing Hospital, London, UK.
Cesarone
M R
MR
Cacchio
M
M
De Sanctis
M T
MT
Santavenere
C
C
D'Auro
M G
MG
Bucci
M
M
Belcaro
G
G
D002908:Chronic Disease; D003238:Connective Tissue / Q000187:drug effects; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D008208:Lymphatic System / Q000187:drug effects; D008833:Microcirculation / Q000187:drug effects; D010936:Plant Extracts / Q000627:therapeutic use*; D014315:Triterpenes / Q000627:therapeutic use*; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000503:physiopathology
D010936:Plant Extracts; C005084:TECA; D014315:Triterpenes